Development of a personalized periodontitis score for patient risk stratification and targeted therapy
Patent Information
- Application Number
- JP2023547748
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-14
- Filing Date
- 2021-10-14
- Publication Date
- 2024-11-11
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current diagnostic tools fail to accurately predict and stratify patients with rapidly progressive periodontitis, leading to costly and harmful overtreatment or insufficient therapy, as they do not account for individual microbial imbalances and demographic variations.
A method using genetic/genomic analysis of bacterial profiles combined with clinical and demographic data to calculate personalized periodontitis scores, enabling site- and patient-specific therapy recommendations based on a reference database and mixed effects modeling.
Enables targeted and individualized treatment approaches by accurately identifying microbial imbalances, reducing overtreatment and ensuring necessary therapy, while monitoring disease progression and treatment effectiveness.
Abstract
Description
Technical Field
[0001] (Technical Field) The present disclosure relates to the development of an individualized periodontitis score for evaluating the microbial imbalance at the individual level in the periodontal pockets and / or saliva of a particular individual at a defined treatment stage, compared to an expected score predicted for an average patient with similar systemic and local medical characteristics and a demographic profile. A microbial profile obtained from gene / genomic information is combined with clinical and demographic information in a mixed effects model to obtain predicted values and standard errors for a given set of clinical parameters. By comparing this predicted mean score with the individualized periodontitis score of an individual patient, information about the relative periodontal disease activity at this site and / or patient is obtained, and thereby the local site and / or patient can be stratified into risk categories and patient-specific targeted treatment modalities can be recommended.
Background Art
[0002] (Background) Periodontitis is the most common non-communicable disease in humans, caused by a destructive interaction between dysbiotic biofilms and dysregulated host immune-inflammatory responses. Periodontitis leads to tooth loss and is independently associated with premature mortality. Oral diseases (many of which are periodontitis) are globally the cause of more years lost to disability than any other human disease. Importantly, the harmful effects, both intra-oral and systemic, are particularly severe in patients with rapidly progressing variants of this disease.
[0003] Periodontitis itself is relatively easy to treat and predictable. However, the real challenge lies in detecting / predicting patients with rapidly progressing disease before permanent damage occurs, and thus identifying those who would benefit from more intensive therapy. This is particularly critical in individuals with comorbid pathological conditions associated with periodontitis and / or risk factors for periodontal disease. Currently, there are no diagnostic tools available to address these challenges.
[0004] Specifically, while there is a considerable amount of published evidence (and some commercial products) indicating single periodontal bacteria, bacterial groups / complexes, or ecological measures of microbial balance / imbalance (see, e.g., Table 1) as markers of disease versus health, and / or the severity of present disease, none of these diagnostic measures allow for stratification of sites or patients related to relative risk by considering the co-occurrence of pathological conditions, local and systemic risk factors, or demographic information. In summary, while previously described molecular microbial measures of periodontitis can provide information about the disease state, they do not reveal whether the level of microbial imbalance—given a clinical situation—is comparable to, substantially worse than, or better than, the average patient with similar characteristics. Only this information enables individualized and targeted therapeutic approaches to individual patients and / or sites that reduce expensive and harmful overtreatment, ensuring that affected individuals receive the treatment they need. [Overview of the project]
[0005] (Description of the invention) The object of the present invention is a method described in claim 1, namely a method for patient and site-specific evaluation of microbial imbalance in periodontitis, describing definitive clinical and demographic parameters: • A process of identifying and quantifying bacterial species using a genetic workflow in samples obtained from periodontal pockets or saliva; The process of calculating a microbial profile based on the amount of one or more bacterial species associated with periodontitis, or the ratio of the amounts of these bacteria; The process of modeling the microbial profile as a function of the selection of relevant clinical and demographic parameters using a reference database; The process of calculating a predicted value of the microbial profile using the above model, with a set of clinical and demographic parameters obtained from the patient; The problem is solved by the method, which includes the step of comparing the microbial profile between predicted values and patient values obtained in the laboratory to assess the relative imbalance of the local microbiome and recommending site and / or patient-specific therapy based thereon.
[0006] This invention is based on an integrated analysis of several key factors that enables innovative stratification and personalized targeted therapy for patients with untreated or treated periodontitis, or patients at risk of developing periodontitis.
[0007] Individualized periodontitis scores include, for example: —Genetic / genomic methods for measuring microbial profiles; —Selection of bacterial species to be evaluated in microbial profiling; —Local and systemic clinical parameters and demographic parameters concerning the patient or site (e.g., samples obtained from an 8 mm pocket (local clinical factor) of a molar in a 51-year-old white Caucasian male (demographic factor) in supportive periodontal care of a non-smoking, otherwise healthy (systemic clinical factor)); and —Determined by a number of parameters selected from the data available in the reference database.
[0008] The biological samples used in this method are obtained from periodontal pockets or saliva. Samples can be collected from all types of periodontal pockets. This requires the presence of a dental professional. Saliva sample collection is extremely reliable and does not require basic equipment or personnel with specialized skills. There are no restrictions on gender, age, origin, or stage of treatment.
[0009] Clinical information refers to all relevant medical information associated with each sample / patient. Relevant clinical parameters in this disclosure include: • Local factors: depth of the pocket at the sample collection site (continuous, expressed in mm), bleeding during probing (binary opposition), type of tooth (category: anterior, premolar, molar), treatment stage (category: untreated, treatment in progress, receiving supportive care); Systemic factors: Smoking status (category: current, past, no history) and diabetes status (category: present / controlled, present / uncontrolled, absent).
[0010] Demographic information is information about groups of people. Relevant demographic parameters in this disclosure include: • Age (continuous, expressed in years); • Gender (Category: Male, Female, Transgender); and (Optional) Race and ethnicity are included.
[0011] The genetic / genomic workflow encompasses all steps from nucleic acid extraction to DNA-DNA hybridization, quantitative PCR, and quantification of the sample based on various genetic methods, including various next-generation sequencing techniques.
[0012] A microbial profile is the quantity of one bacterial species or a collection of several bacterial species identified as important markers of periodontitis or periodontal health, or, as an expanded form, the ratio between selected collections of species. A microbial profile can be calculated based on the number of any bacterial species identified as important markers of periodontitis or periodontal health. Several bacterial species means selected from 2 to 700 bacterial species (i.e., the number of known common phylogenetic types in the human mouth). The number of bacterial species identified as important markers is at least 1, preferably 2 to 700, more preferably 2 to 600, 2 to 500, 2 to 400, 2 to 300, 2 to 200, or 2 to 100. Most preferably, the number of bacterial species identified as important markers is 2 to 90, 2 to 80, 2 to 70, 2 to 60, 2 to 50, 2 to 40, 2 to 30, 2 to 20, or 2 to 10. In a particularly preferred embodiment, the number of bacterial species identified as important markers is 1, 2, 3, or 4, and the bacterial species are listed in Table 1. The unit of the microbial profile is based on the genetic / genomic method used. For example, the unit of the microbial profile by next-generation sequencing (NGS) is NGS reads.
[0013] The reference database contains the following information about multiple samples obtained from various body parts and patients: • Local and systemic clinical information as outlined above; • Demographic information as outlined above; and • Accumulate microbial profiles for given genetic / genomic methods and bacterial species selection.
[0014] This reference database is an essential component for calculating the individualized periodontitis score.
[0015] A given combination of clinical and demographic information can be used to stratify sites and / or patients derived from a reference database. Within a particular stratification, it is expected that patients will have higher individualized periodontitis scores to present one or more well-established risk factors for this disease, such as age and smoking status—indicating a higher level of microbial imbalance and therefore increased disease activity. A typical stratification for the reference database might be smoking men aged 50–59 years.
[0016] A defined set of clinical and diagnostic parameters is required to calculate the mean expected score and individualized periodontitis score for a given selection of genetic / genomic methods and microbial profiles. As an example of this disclosure, the inventors calculated scores for three microbial profiles for a 51-year-old non-smoking man. A linear mixed-effects model for the selection of parameters in this reference database is used to calculate the mean expected score and the standard error associated with this mean. The linear mixed-effects model used in the method of the present invention is known to those skilled in the art and is described in Brown's literature, 2021, in particular with respect to the description of the linear mixed-effects model on pages 1-19, the disclosure of which is fully incorporated herein. The individualized periodontitis score obtained from the sample collection site is calculated directly using the selected genetic method (amount of one or more bacterial species) and compared with the mean expected score and associated standard error obtained using the modeling and reference database.
[0017] Individualized periodontitis scores within -1 SE and within 1 SE of the predicted mean expected score represent the most typical range of values. In a preferred embodiment, a decreased score has an individualized periodontitis score less than -1 SE from the predicted value. In a more preferred embodiment, an increased score has an individualized periodontitis score less than -1 SE from the predicted value.
[0018] Based on the above, bacterial quantities can be detected using a variety of molecular methods, including checkerboard DNA-DNA hybridization, quantitative PCR, 16S amplicon sequencing, whole-genome DNA sequencing / metagenomics, and / or RNA metatranscriptome sequencing. The present invention is based on the detection of a microbial profile, which is a measure of the absolute or relative quantity of one or more marker bacteria associated with periodontitis or periodontal health (Table 1). All types of microbial profiles can be used for the present invention. In some cases, a microbial dysbiosis index or subgingival microbial dysbiosis index is used as the microbial profile in the method of the present invention. Preferred microbial dysbiosis indices are described, for example, in the literature by Gevers, Kugathasan et al., 2014, which is fully incorporated herein. Preferred subgingival microbial dysbiosis indices are described, for example, in the literature by Chen, Marsh et al., 2021, which is fully incorporated herein. The term microbial profile as used in the rest of this document interchangeably refers to one of the molecular indices in Table 1 or any other conceivable microbial profile.
[0019] The microbial dysbiosis index is defined as the logarithm of the total abundance of disease-related microorganisms in patient samples, relative to the total abundance of microorganisms that decrease in periodontitis for all samples. The microbial dysbiosis index shows a strong positive correlation with clinical disease severity and a negative correlation with species richness, demonstrating a strong decrease in species diversity where more severe disease conditions favor more extreme dysbiosis.
[0020] The subgingival microbial dysbiosis index is defined as the difference between the average centralized log-ratio abundance of periodontitis-related species / genera and the average centralized log-ratio abundance of healthy-state-related species / genera, using the following method / formula: Mean CLR abundance in dysbiosis (DS / DG) - Mean CLR abundance in normobiosis (DS / DG) It can be calculated according to the following. The subgingival microbial dysbiosis index shows high reproducibility, a strong positive correlation with clinical disease severity, and can distinguish periodontitis and healthy states with high accuracy.
[0021] (Table 1: Example of microbial profile) The microbial profile is a measure of the amount of one or several bacterial species or the ratio of selected species that have been identified as important markers for periodontitis or periodontal health. All of these microbial profiles are in the public domain, and this disclosure is not intended to claim any rights to any of these profiles. These measures are merely intended to illustrate the use of the present invention, and an individualized periodontitis score that compares any microbial profile obtained from a specific patient sample using the above molecular techniques with the expected average score of patients with similar characteristics is intended to identify samples that deviate significantly from this average and to change the treatment method. [Table 1]
[0022] Based on the above description, the present invention is based on a combination of local and systemic clinical and demographic parameters for a microbial profile, for example, one of the profiles given in Table 1, for a site and / or patient. As described in the above summary, clinical information means all relevant medical information associated with each sample / patient. The relevant clinical parameters of this disclosure include: · Local factors: Pocket depth at the sample collection site (continuous, expressed in mm), bleeding on probing (binary), tooth type (category: anterior teeth, premolars, molars), treatment stage (category: untreated, in treatment progress, during supportive therapy); · Systemic factors: Smoking status (category: current, past, no experience) and diabetes status (category: yes / regulated, yes / unregulated, no).
[0023] Demographic information is information about groups of people. The relevant demographic parameters of this disclosure include: • Age (continuous, expressed in years); • Gender (Category: Male, Female, Transgender); and (Optional) Race and ethnicity are included.
[0024] Next, a linear mixed-effects model is used to calculate individualized periodontitis scores for each microbial profile, taking into account the above clinical and demographic characteristics, and, if applicable, multiple samples per patient. The linear mixed-effects model is an extension of the simple linear model, allowing for both fixed effects (e.g., defined pocket depth) and random effects (e.g., multiple samples per subject). The simple linear model includes a simple linear regression where the dependent variable Y can be modeled by the dependent variable X. The response variable in the mixed model is the individualized periodontitis score for each patient or site. Clinical and demographic parameters represent the explanatory variables in this model. Pocket depth, sex, age, smoking status, and diabetes status are fixed effects, while patient identity is a random effect. In detail, the equation for the linear mixed-effects model is as follows: Individualized Periodontitis Score ~ Local Clinical Factors + Systemic Clinical Factors + Demographic Factors + (1|Patient) It can be expressed as follows.
[0025] The parameters derived from this equation have the following units: • Local clinical factors: depth of pocket at the sample collection site (continuous, expressed in mm), bleeding on probing (binary opposition), type of tooth (category: anterior, premolar, molar), treatment stage (category: untreated, treatment in progress, receiving supportive care); • Systemic clinical factors: Smoking status (category: current, past, no history) and diabetes status (category: present / controlled, present / uncontrolled, absent). Demographic information is information about groups of people. Relevant demographic parameters in this disclosure include: age (continuous, expressed in years), sex (categories: male, female, transgender), and (optionally) race and ethnicity. • Patient – A numerical identifier in the clinical database (e.g., insurance number).
[0026] Based on the above, site- or patient-related individualized periodontitis scores obtained from patients in the laboratory can be compared to the mean expected score using the same clinical and demographic parameters for all past patient samples. For example, a set of clinical parameters may include: Pocket depth = 5 mm, Gender = Male, Age = 51 years old, Smoking status = Non-smoker, Diabetes status = Present. It can be defined as follows. The predicted values of the model based on the determined clinical parameters represent values corrected for many possible confounding factors. This model is also used to calculate the + / -1 standard error (SE) around the predicted values as a measure of uncertainty. The predicted values and standard errors can be calculated for all combinations of clinical parameters that are theoretically incorporated into the model.
[0027] For a given set of clinical parameters, the predicted expected mean score and standard error can be used as a reference for comparison with individualized periodontitis scores for patients or sites obtained in the laboratory.
[0028] The Individualized Periodontitis Score is a single value that can be repeatedly measured for the same sample site / patient to determine and monitor the stage of the disease during all treatment stages, including primary and secondary prevention. In other words, score values can be compared for different samples taken from the same site but at different times.
[0029] Individualized periodontitis scores have the advantage of being able to be systematically calculated based on a patient's periodontal pockets or saliva using various molecular methods. In other words, it is possible to calculate and compare individualized periodontitis scores using the same molecular method.
[0030] While the model is established, the predicted values and standard errors of the individualized periodontitis score based on the set of clinical parameters are dynamic. These values change when new entries are added to the reference database used. Given that an increase in data points is associated with a decrease in variance, the certainty of prediction increases over time.
[0031] Patient and site-specific characterization (dental or oral cavity) is performed by comparing individualized periodontitis scores (via multiple sample and / or saliva sampling) for specific periodontal pockets or oral cavities with predicted scores for a specific set of clinical parameters using a linear mixed-effects model. Patients with samples showing a decrease or increase in individualized periodontitis scores indicate microbial imbalance and will receive targeted treatment different from the treatment schedule recommended for patients with individualized periodontitis scores similar to the mean predicted score.
[0032] Targeted therapy includes regular treatment and management, and does not recommend intensive treatment / management including additional antimicrobial measures, the use of disinfectants, or targeted use of local or systemic antibiotics if the disease is systemic.
[0033] Specifically, samples characterized by an individualized periodontitis score that is more than one standard error higher than the predicted expected mean score for a given clinical and demographic situation are considered to indicate an increase in microbial imbalance.
[0034] Conversely, for a given set of clinical and demographic parameters, a decrease of more than 1 SE in the individualized periodontitis score compared to the predicted mean expected score indicates that a portion of the population has a lower-than-average microbial imbalance, or in other words, that the periodontal pockets exhibit a more mutually beneficial profile than the rest of the sampled population.
[0035] Finally, for a given set of clinical and demographic parameters, an individualized periodontitis score being within -1 SE and 1 SE of the predicted mean expected score indicates a range of most typical values, in other words, a situation that reflects the profile of a population with an average microbial balance, or in other words, that the periodontal pocket reflects the mean profile of dysbiosis in the sampled population.
[0036] This approach provides representative and generalizable insights into site- and patient-specific levels of microbial balance and enables recommendations for targeted therapies, including individualized, intensive approaches involving supervised topical or systemic adjunct disinfectants or antibiotics.
[0037] Microbial imbalances can be categorized as follows: Individualized periodontitis score less than -1 SE from the average expected score: Regular treatment and management without recommending additional antimicrobial measures; Individualized periodontitis score of -1 SE to +1 SE: Mild microbial imbalance (corresponding to the early stage of dysbiosis), requiring intensive treatment / management including the use of disinfectants; Individualized periodontitis score above +1 SE: Severe microbial imbalance (corresponding to the stage of progressive dysbiosis), requiring highly intensive treatment / strictly scheduled management, including targeted use of local or systemic antibiotics if the disease is systemic.
[0038] In addition to an absolute measure of the level of mutualism / dysbiosis, as detailed above, patient and site-specific characterization is performed by comparing an individualized periodontitis score for a specific periodontal pocket or oral cavity with the mean expected score for this clinical severity based on data from a reference database, while taking into account the confounding factors (local and systemic clinical factors, demographic factors) using regression. Specifically, samples characterized by an individualized periodontitis score that is one standard error higher or lower than the mean expected score for a given disease severity are considered to indicate increased or significantly increased dysbiosis or mutualism, respectively. This approach provides representative and generalizable insights into the level of site and patient-specific dysbiosis and enables the recommendation of targeted therapies, including individualized intensive approaches with supervised topical or systemic adjunct disinfectants or antibiotics.
[0039] The methods of the present invention, particularly the individualized periodontitis score, have the advantage of being able to determine the microbial imbalance in periodontal pockets and / or oral cavity at the individual level and appropriately stratify individuals and / or sites for targeted, individualized therapeutic interventions. These include various anti-infective and / or periodontal maintenance interventions performed by a dentist or dental team, which, if present, can influence the microbial imbalance and thereby avoid overtreatment while simultaneously preventing unnecessary and irreversible loss of periodontal tissue.
[0040] Furthermore, the host response can be estimated using the methods of the present invention, particularly the individualized periodontitis score. This is because, even if the individualized periodontitis score measures the relative amount of the microbial profile, it has been shown that these microbial profiles are directly affected by an unbalanced host response.
[0041] The method of the present invention, in particular the individualized periodontitis score, has the advantage of being able to be used to monitor the progression of stages and the development of the microbial balance in a given periodontal pocket or the entire oral cavity over time. A biological or salivary sample obtained from one of several periodontal pockets can be collected at a given time interval to monitor the progression of the microbial balance in the periodontal pocket or oral cavity. Suitable and preferred time intervals for collecting samples are, for example, every day, every two days, every three days, every four days, every five days, every week, every two weeks or every three weeks, or every month to a maximum of every five months.
[0042] The method of the present invention, in particular the personalized periodontitis score, has the advantage that it can be used to confirm and monitor the effectiveness of treatment for a given patient. After a given treatment, the personalized periodontitis score should decrease as a result of improved microbial balance. If the personalized periodontitis score remains the same or increases, switching to a different, more suitable antibiotic is a recommended strategy to improve treatment success. Monitoring the effectiveness of periodontitis treatment preferably involves analyzing samples taken from periodontal pockets after or between treatments at predetermined time intervals, e.g., every day, every two days, every three days, every four days, every five days, every week, every two weeks or every three weeks, or every month to a maximum of every five months.
[0043] The method of the present invention, in particular the individualized periodontitis score, has the advantage of being able to be used to compare results from different sources, such as dental clinics or research teams. The complexity of the microbial community in the periodontal pocket is summarized in a single numerical value (predicted value) and range (-1 SE to +1 SE) using a given method, and the method is obvious and does not refer to other samples or databases.
[0044] The method of the present invention, in particular the personalized periodontitis score, has the advantage of being usable as a numerical proxy for monitoring other diseases. Indeed, periodontitis is associated with a great many diseases, including cardiovascular diseases such as diabetes, coronary heart disease and stroke, chronic respiratory diseases, and rheumatoid arthritis. Patients with a high personalized periodontitis score, which characterizes relative microbial imbalance in the periodontal pocket or oral cavity, may have a higher risk of all of the above diseases.
[0045] Molecular methods for detecting bacteria in periodontal pockets are well known. These methods include, in particular, checkerboard DNA-DNA hybridization, quantitative PCR, next-generation sequencing including 16S ribosomal RNA sequencing, metagenomics, and metatranscriptomics.
[0046] The present invention further relates to combinations of microbial profiles consisting of one or more bacterial species that serve as important markers of periodontitis and / or periodontal health. The present invention extends to all other microbial profiles resulting from one or more important bacteria that are positively or negatively associated with periodontitis, including indices that quantify ecological measures of microbial imbalance, such as microbial dysbiosis.
[0047] The present invention is further illustrated in three examples, illustrated by three figures relating to microbial profiles including 1) Porphyromonas gingivalis, 2) the red complex (Porphyromonas gingivalis + Tannerella forsythia + Treponema denticola), and 3) a pathogenic bacteria complex (Aggregatibacter actinomycetemcomitans + Porphyromonas gingivalis + Tannerella forsythia + Treponema denticola). [Brief explanation of the drawing]
[0048] (Brief description of the drawing) [Figure 1] The predicted value (represented by squares) for Porphyromonas gingivalis in a 51-year-old non-smoking male is shown, based on calculations using the above model and a quantitative PCR dataset related to clinical data. As an example, the standard error based on the predicted value and a hypothetical patient value (represented by triangles) is shown for a pocket depth of 4 mm. If the hypothetical patient value exceeds +1 SE from the mean expected score, the patient requires highly intensive treatment / strictly scheduled management. [Figure 2] The predicted value of the red complex (represented by a square) for a 51-year-old non-smoking male is shown, based on calculations using the above model and a quantitative PCR dataset related to clinical data. As an example, the standard error based on the predicted value and a hypothetical patient value (represented by a triangle) is shown for a pocket depth of 4 mm. If the hypothetical patient value exceeds +1 SE from the mean expected score, the patient requires highly intensive treatment / strictly scheduled management. [Figure 3] The predicted value (represented by a square) for the causative bacterial complex in a 51-year-old non-smoking male is shown, based on calculations using the above model and a quantitative PCR dataset related to clinical data. As an example, the standard error based on the predicted value and a hypothetical patient value (represented by a triangle) is shown for a pocket depth of 4 mm. If the hypothetical patient value exceeds +1 SE from the mean expected score, the patient requires highly intensive treatment / strictly scheduled management.
[0049] (Example 1: Predictive modeling of molecularly individualized periodontitis score for quantitative PCR data) (Materials and methods for calculating and modeling microbial profiles) The dataset is from scientific papers: Reference Tomas I, Regueira-Iglesias A, Lopez M, Arias-Bujanda N, Novoa L, Balsa-Castro C and Tomas M (2017) Quantification by qPCR of Pathobionts in Chronic Periodontitis: Development of Predictive Models of Disease Severity at Site-Specific Level. Front. Microbiol. 8:1443. doi:10.3389 / fmicb.2017.01443 This information was obtained from the supplementary material "DATA SHEET S1 | Data Frames and Univariate Analysis".
[0050] The dataset consists of quantitative PCR (qPCR) information on various bacteria associated with periodontitis (the "concentration pg" column in the "qPCR data" tab). The dataset also includes clinical information ("clinical data" tab), including patient identity, age, sex, smoking status (four first columns), and pocket depth (in both the "PPD_control" column for control sites and the "PPD_Perio" column for periodontitis sites). Information on diabetic status was not available in this dataset and therefore could not be included in the analysis.
[0051] (statistics) All analyses were performed using R software with custom-designed scripts. Clinical and qPCR information was fitted using patient IDs. The following microbial profiles obtained from Table 1 illustrate the present invention: Profile #1 represents the concentration of the bacterium Porphyromonas gingivalis, expressed in pg. • Profile #2 – The Red Complex was calculated as the sum of the "concentration pg" columns for the bacteria Porphyromonas gingivalis, Tanerella forsythia, and Treponema denticola. • Profile #3 – Ecological bacterial load was calculated as the sum of the "concentration pg" columns for the bacteria Aggregatibacter actinomycete mucromitans + Porphyromonas gingivalis + Tanerella forsythia + Treponema denticola.
[0052] Using the lme4 package in R, create the following linear mixed-effects model with parameters for a given category: lmer(microbiological profile ~ pocket depth + sex + age + smoking status + (1|patient ID)) We obtained the mean expectation and the standard error associated with this mean individualized periodontitis score.
[0053] Next, using this model, we obtained the mean predicted values and standard errors of various molecular profiles used for this demonstration for a defined set of parameters: pocket depth of 4–10 mm, sex as male, age as 51 years, and smoking status as non-smoker. The selection of pocket depth values of 4–10 mm represents mild, moderate, and severe cases and does not include cases at risk due to periodontal-endodontic defects with various pathophysiological features. As expected, the predicted values of the microbial profiles for this set of clinical parameters showed a positive correlation with pocket depth for all microbial indices used.
[0054] Next, using the figures and tables, we can compare the values for three different microbial profiles. In this example, the inventors set profile #1 to 400 pg / μl, profile #2 to 1000 pg / μl, and profile #3 to 1250 pg / μl, with a pocket depth of 4 mm and other clinical parameters being equivalent. For all three microbial profiles, the values were clearly above the mean expected score by +1 SE. In these situations, the pocket has a high degree of dysbiosis and will likely require highly intensive treatment with antibiotics and tightly scheduled management.
[0055] (References) Table 2
Claims
1. 1. A method for obtaining data for patient- and site-specific assessment of microbial imbalance in periodontitis based on clinical and demographic parameters, comprising: - Identifying and quantifying bacterial species using a genetic workflow in samples obtained from periodontal pockets or saliva; - calculating a microbial profile based on the amount of one or several bacterial species associated with periodontitis or on the ratio of the amounts of these bacteria; - using a reference database to model the microbial profile as a function of a selection of relevant clinical and demographic parameters; - calculating a predictive value of said microbial profile via said model using a set of clinical and demographic parameters obtained from the patient; and - comparing said microbial profile between said predicted values and laboratory obtained patient values to assess relative imbalances in the local microbiome and recommend site and / or patient specific therapy based thereon; The clinical parameter is Local factors: pocket depth at the sampling site, bleeding on probing, tooth type, and treatment stage selected from untreated, ongoing, and supportive care; and Systemic factors: including smoking status and diabetic status; The demographic parameters are: ·age; Gender; and - optionally including race and ethnicity, A linear mixed-effects model based on molecular and clinical data from a reference database is used to model the microbial profile, the model including the microbial profile as a response variable and clinical parameters including pocket depth as explanatory variables. The method.
2. 2. The method of claim 1, wherein the microbial profile is defined as the amount of one or several bacterial species identified as important markers of periodontitis, where several bacterial species means selected from between 2 and 700 bacterial species, representing the number of known common phylotypes in the human mouth.
3. The method of claim 1, wherein the microbial profile is selected from ecological measures of microbial imbalance, such as indices quantifying microbial dysbiosis, in particular a microbial dysbiosis index or a subgingival microbial dysbiosis index.
4. The method of any one of claims 1 to 3, wherein the linear mixed effects model is used to predict the standard error for any combination of the microbial profile and parameters used in the model.
5. The method of any one of claims 1 to 4, wherein the microbial profile of additional patients with defined clinical parameters can be compared with the predicted value and standard error based on the same clinical parameters.
6. Microbial imbalance stages are: healthy stage, where the individualized periodontitis score was less than −1 SE from the predicted value; early dysbiosis stage, with individualized periodontitis scores between −1 SE and +1 SE from the predicted value; 6. The method of any one of claims 1 to 5, wherein the individualized periodontitis score is defined as an advanced dysbiosis stage exceeding a value of +1 SE from the predicted value.
7. The method according to any one of claims 1 to 6, wherein the bacterial species is identified by quantitative PCR, 16S ribosomal RNA sequencing, shotgun sequencing or any other molecular technique.
8. Use of the method according to any one of claims 1 to 7 for determining the severity of periodontitis.
9. 10. Use of the method according to any one of claims 1 to 8 for monitoring the development of dysbiosis in periodontitis over time.
10. 10. Use of the method according to any one of claims 1 to 8 for monitoring the effectiveness of a periodontitis treatment.
11. Use of the method according to any one of claims 1 to 8 for recommending and selecting a treatment strategy for periodontitis.
12. 9. A method for monitoring the development of dysbiosis in periodontitis comprising a method according to any one of claims 1 to 8, wherein samples taken from the periodontal pocket at defined time intervals, such as every 1 day, every 2 days, every 3 days, every 4 days, every 5 days, every 1 week, every 2 weeks or every 3 weeks, or every 1 month up to 5 months, are analysed.
13. 9. A method for monitoring the effectiveness of periodontitis treatment comprising the method according to any one of claims 1 to 8, comprising analysing samples taken from the periodontal pocket after or during said treatment at predetermined time intervals, for example every 1 day, every 2 days, every 3 days, every 4 days, every 5 days, every 1 week, every 2 weeks or every 3 weeks, or every 1 month up to 5 months.
